CEL-SCI Corp - Company Profile
Powered by 
All the data and insights you need on CEL-SCI Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date CEL-SCI Corp Strategy Report
- Understand CEL-SCI Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CEL-SCI Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of CEL-SCI Corp Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 17 Mar 2016 | Lorem |
| Cel-Sci plans initial data analysis at about 300 deaths in Phase III head/neck cancer trial with Multikine – CEO | 12 Jun 2014 | Kathleen Raven |
| Cel-Sci's Phase III head and neck cancers study with Multikine likely to score all country approvals by May 2014 - exec | 13 Dec 2013 | Sarah Bruyn Jones |
| Cel-Sci replaced CRO, likely Pharmanet, with Aptiv and Ergomed after Phase III cancer trial recruitment stalled | 01 May 2013 | Casey McDonald |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer